Medicines labeled for the same conditions
Alternatives to daratumumab and hyaluronidase
6 other medicines are given the same way (subcutaneous) and in the same FDA class as daratumumab and hyaluronidase or labeled mainly for the same use (leukemia, lymphoma and myeloma); 1 is in its class, cd38-directed cytolytic antibodies: isatuximab; the others include 1 bispecific cd20-directed cd3 t cell engager (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as daratumumab and hyaluronidase?
Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Daratumumab and hyaluronidasecd38-directed cytolytic antibody | this medicine | none listed | n/a | No | No current entry |
| Isatuximabcd38-directed cytolytic antibody · same class | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Elranatamab | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Epcoritamabbispecific cd20-directed cd3 t cell engager | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Mosunetuzumab | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Talquetamab | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Teclistamab | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Daratumumab and hyaluronidase: the full record
- label, generics, price, shortages, recalls